Preventing VTE in Cancer, Maintaining Low Bleeding Risk: Reduced-Dose Apixaban
Mario Balsa, medical oncology resident at Institut Català d’Oncologia, shared an insightful post on X:
” ‘New’ The New England Journal of Medicine (NEJM) study in 1,766 patients with cancer-associated VTE:
- Reduced-dose apixaban (2.5mg BID) vs full dose (5mg BID)
- VTE recurrence: 2.1% vs 2.8%
- Clinically relevant bleeding: 12.1% vs 15.6%
Same protection, less bleeding. Sometimes, less really is more!”
Effects of reduced dose of an oral anticoagulant on thromboembolic events and bleeding are discussed in the new study ”Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism” published by Isabelle Mahé et al. in the New England Journal of Medicine (NEJM).
In patients with active cancer and venous thromboembolism, extended treatment with reduced-dose apixaban was as effective as the full dose in preventing recurrent events.
Moreover, dose reduction resulted in fewer bleeding complications.
This supports reduced-dose apixaban as a safer alternative for long-term anticoagulation in this population.
Never miss the scientific advancements in the World of Hematology, read Hemostasis Today.
-
Jan 30, 2026, 11:38Aaron Rodriguez Calienes on Intracranial Stenting: Rescue vs First-Line Outcomes
-
Jan 30, 2026, 11:25Ahmed Nasreldein on Sex Disparities in Thrombolysis Delay Among Egyptian Stroke Patients
-
Jan 30, 2026, 11:17Yanki Yarman: My PhD Project Has Been Published in Blood!
-
Jan 30, 2026, 11:08Alexandros Apostolou on Complications Associated with IDU and Thrombophilia
-
Jan 30, 2026, 10:57Peisong Ma on GRK5 Polymorphism Affecting Platelets
-
Jan 30, 2026, 10:47Ashok Yadav Explains Fetal Thrombotic Vasculopathy: FTV
-
Jan 30, 2026, 10:34Saif ur Rahman Compares K2 and K3 EDTA: Key Differences Explained
-
Jan 30, 2026, 10:22Manpreet Gill on Heparin Resistance: When 14 Years of Experience Finally Gets a Plot Twist
-
Jan 30, 2026, 10:14Mohamed Elsaid on The Role of Hyperlipidemia in Thrombogenesis